Hagens Berman Sobol Shapiro LLP, a national investor-rights law firm, alerts investors with losses over $50,000 of the January 22, 2016 lead plaintiff deadline in the securities fraud class action lawsuit filed against Osiris Therapeutics, Inc. (NASDAQ:OSIR).
If you suffered losses because of your purchase of Osiris securities between May 12, 2014 and November 20, 2015, contact Hagens Berman Partner Reed Kathrein, who is leading the firm’s investigation, by calling (510) 725-3000, emailing [email protected] or visiting https://www.hbsslaw.com/cases/OSIR. The lawsuit was filed in the U.S. District Court for the District of Maryland and investors have until January 22, 2016 to move the court to act as lead plaintiff.
The complaint accuses the defendants of violations of the securities laws because Osiris failed to disclose during the Class Period that the Company overstated revenues from several contracts and failed to follow Generally Accepted Accounting Principles.
The news shocked investors when announced on November 16, 2015. Osiris disclosed that if they correctly recognized revenue for three contracts, it would result in substantial decreases in product revenues in 2014 and the first and second quarters of 2015. In addition, Osiris announced that these restatements would result in the Company missing its revenue targets in three of the last four quarters. Following this news of an accounting restatement, Osiris shares fell, dropping $3.02, or 21.53%, to close at $10.97 on November 17, 2015.
If you lost more than $50,000 in your investments in Osiris securities between May 12, 2014 and November 20, 2015 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.
Whistleblowers: Persons with non-public information regarding Osiris should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at (510) 725-3000 or email [email protected].
Hagens Berman is headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. Read the Firm’s Securities Newsletter at http://www.hbsslaw.com/hagens-berman-investor-fraud-center/securitites-newsletter, and visit the blog at www.meaningfuldisclosure.com.


Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push
Unilever and Magnum Face Defamation Lawsuit Over Ben & Jerry's Board Chair Dismissal
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
NAB Plans to Cut 170 Jobs While Expanding Offshore Operations
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 



